Roussy

Rou·ssy

(rū-sē'),
Gustave, French pathologist, 1874-1948. See: Roussy-Lévy disease, Roussy-Lévy syndrome, Dejerine-Roussy syndrome.
References in periodicals archive ?
Professor Alexander Eggermont is the general director of cancer centre Gustave Roussy in Paris and a physician in the melanoma space.
He is the general director of cancer center Gustave Roussy in Paris and a highly respected expert physician in the melanoma space.
His Highness the Prime Minister Sheikh Jaber Al-Mubarak Al-Hamad Al-Sabah received Chairman of Gustave Roussy Institute of Oncology Alexander Eggermont KUWAIT, April 3 (KUNA) -- His Highness the Prime Minister Sheikh Jaber Al-Mubarak Al-Hamad Al-Sabah received, in the presence of Health Minister Sheikh Dr.
Sergey Nikolaev, Researcher, Gustave Roussy Cancer Center; France; and Dr.
ISLAMABAD -- The Swiss Ambassador Mr Thomas Kolly visited Comsats University Islamabad (CUI) on Friday on invitation of the CUI Rector with a three-member Swiss delegation comprising of Prof Stylianos E Antonarakis, University of Geneva Medical School, Switzerland; Prof Sergey Nikolaev, Researcher, Gustave Roussy Cancer Center; France;and Dr Muhammad Ansar, University of Geneva Medical School, Switzerland.
Des etudes anterieures ont deja demontre que ces traitements anti-acide, comme l'omeprazole (Mopral), l'esomeprazole (Inexium) ou la ranitidine (Azantac), reduisaient le taux de pazopanib dans le sang de patients atteints de tumeurs solides, rappelle l'institut Gustave Roussy. "Les comprimes de pazopanib pris par voie orale doivent passer dans un milieu acide, c'est-a-dire dans l'estomac, pour se dissoudre.
Antonio Di Meglio, study author and Medical Oncologist, Institut Gustave Roussy, France.
Kuwait will build a branch of the France-based cancer research institute Gustave Roussy, as part of the government's vision to build more hospitals.
The principal investigator initiating this trial is Aurelien Marabelle, MD, PhD, Clinical Director of the Cancer Immunotherapy Program at Institut Gustave Roussy, Villejuif, France.
Eggermont, M.D., Ph.D., from Gustave Roussy Cancer Campus Grand Paris, and colleagues randomized patients with completely resected stage III melanoma to receive 200 mg pembrolizumab (514 patients) or placebo (505 patients) intravenously every three weeks for 18 doses.
Eggermont is with Cancer Institute Gustave Roussy, University Paris-Sud, France.